Genetic engineering of T cells for adoptive immunotherapy
- PMID: 18841331
- PMCID: PMC2699549
- DOI: 10.1007/s12026-008-8057-6
Genetic engineering of T cells for adoptive immunotherapy
Abstract
To be effective for the treatment of cancer and infectious diseases, T cell adoptive immunotherapy requires large numbers of cells with abundant proliferative reserves and intact effector functions. We are achieving these goals using a gene therapy strategy wherein the desired characteristics are introduced into a starting cell population, primarily by high efficiency lentiviral vector-mediated transduction. Modified cells are then expanded using ex vivo expansion protocols designed to minimally alter the desired cellular phenotype. In this article, we focus on strategies to (1) dissect the signals controlling T cell proliferation; (2) render CD4 T cells resistant to HIV-1 infection; and (3) redirect CD8 T cell antigen specificity.
Figures




Similar articles
-
Strategies to genetically engineer T cells for cancer immunotherapy.Cancer Immunol Immunother. 2016 Jun;65(6):631-49. doi: 10.1007/s00262-016-1842-5. Epub 2016 May 2. Cancer Immunol Immunother. 2016. PMID: 27138532 Free PMC article. Review.
-
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.Trends Mol Med. 2016 Dec;22(12):1000-1011. doi: 10.1016/j.molmed.2016.10.002. Epub 2016 Nov 4. Trends Mol Med. 2016. PMID: 27825667 Free PMC article. Review.
-
Armed T cells with CAR for cancer immunotherapy.Sci China Life Sci. 2016 Apr;59(4):331-2. doi: 10.1007/s11427-016-5047-0. Epub 2016 Apr 15. Sci China Life Sci. 2016. PMID: 27080712 No abstract available.
-
Adoptive therapy with CAR redirected T cells for hematological malignancies.Sci China Life Sci. 2016 Apr;59(4):370-8. doi: 10.1007/s11427-016-5036-3. Epub 2016 Mar 22. Sci China Life Sci. 2016. PMID: 27009302 Review.
-
Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen receptor.Methods Mol Biol. 2014;1139:177-87. doi: 10.1007/978-1-4939-0345-0_16. Methods Mol Biol. 2014. PMID: 24619680
Cited by
-
Th17 cells in cancer: the ultimate identity crisis.Front Immunol. 2014 Jun 17;5:276. doi: 10.3389/fimmu.2014.00276. eCollection 2014. Front Immunol. 2014. PMID: 24987392 Free PMC article. Review.
-
Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.Immunol Res. 2021 Dec;69(6):471-486. doi: 10.1007/s12026-021-09236-x. Epub 2021 Sep 23. Immunol Res. 2021. PMID: 34554405 Free PMC article. Review.
-
CRISPRed Macrophages for Cell-Based Cancer Immunotherapy.Bioconjug Chem. 2018 Feb 21;29(2):445-450. doi: 10.1021/acs.bioconjchem.7b00768. Epub 2018 Jan 22. Bioconjug Chem. 2018. PMID: 29298051 Free PMC article.
-
Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.J Immunother. 2011 May;34(4):343-52. doi: 10.1097/CJI.0b013e3182187600. J Immunother. 2011. PMID: 21499127 Free PMC article.
-
High-throughput discovery of MHC class I- and II-restricted T cell epitopes using synthetic cellular circuits.Nat Biotechnol. 2025 Apr;43(4):623-634. doi: 10.1038/s41587-024-02248-6. Epub 2024 Jul 2. Nat Biotechnol. 2025. PMID: 38956325 Free PMC article.
References
-
- Heslop HE, Perez M, Benaim E, Rochester R, Brenner MK, Rooney CM. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apher. 1999;14:154–6. - PubMed
-
- Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038–44. - PubMed
-
- Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2006;107:1325–31. - PubMed
-
- Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007;27:406–16. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials